Teva Pharmaceutical Industries Ltd (TEVA) Stake Lowered by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp cut its stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 17.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 150,922 shares of the company’s stock after selling 30,900 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Teva Pharmaceutical Industries were worth $2,327,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Bruderman Asset Management LLC grew its position in Teva Pharmaceutical Industries by 2,175.0% in the fourth quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock worth $36,000 after acquiring an additional 2,262 shares in the last quarter. Rational Advisors LLC purchased a new position in Teva Pharmaceutical Industries in the fourth quarter worth $49,000. Capital Investment Advisory Services LLC purchased a new position in Teva Pharmaceutical Industries in the fourth quarter worth $56,000. Quadrant Capital Group LLC grew its position in Teva Pharmaceutical Industries by 420.3% in the fourth quarter. Quadrant Capital Group LLC now owns 5,541 shares of the company’s stock worth $80,000 after acquiring an additional 4,476 shares in the last quarter. Finally, Whittier Trust Co. grew its position in Teva Pharmaceutical Industries by 35.4% in the fourth quarter. Whittier Trust Co. now owns 5,481 shares of the company’s stock worth $84,000 after acquiring an additional 1,434 shares in the last quarter. Institutional investors own 66.42% of the company’s stock.

In other news, insider Deborah A. Griffin sold 4,107 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $16.88, for a total transaction of $69,326.16. Following the completion of the transaction, the insider now directly owns 2,941 shares of the company’s stock, valued at $49,644.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Hafrun Fridriksdottir sold 1,643 shares of the company’s stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $15.70, for a total transaction of $25,795.10. Following the transaction, the vice president now directly owns 13,469 shares of the company’s stock, valued at $211,463.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,173 shares of company stock valued at $273,316. Insiders own 0.43% of the company’s stock.

Shares of NYSE:TEVA opened at $16.51 on Friday. The stock has a market cap of $16.78 billion, a PE ratio of 5.90, a PEG ratio of 2.96 and a beta of 1.34. The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 1.69. Teva Pharmaceutical Industries Ltd has a 12 month low of $14.59 and a 12 month high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, February 13th. The company reported $0.53 EPS for the quarter, meeting the consensus estimate of $0.53. The firm had revenue of $4.56 billion during the quarter, compared to the consensus estimate of $4.52 billion. Teva Pharmaceutical Industries had a negative net margin of 11.40% and a positive return on equity of 18.57%. The company’s quarterly revenue was down 15.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.93 earnings per share. On average, equities analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.33 earnings per share for the current year.

Several research firms have weighed in on TEVA. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research note on Monday, December 3rd. Credit Suisse Group set a $26.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Thursday, December 13th. ValuEngine downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Bank of America raised shares of Teva Pharmaceutical Industries from an “underperform” rating to a “buy” rating and set a $16.12 price target for the company in a research note on Thursday, January 3rd. Finally, UBS Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a research note on Wednesday, January 23rd. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $21.21.

TRADEMARK VIOLATION NOTICE: This report was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2019/03/17/teva-pharmaceutical-industries-ltd-teva-stake-lowered-by-british-columbia-investment-management-corp.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: What is dollar cost averaging (DCA)?

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply